Jonathan Prenner, MD
Retina Specialist · New Brunswick, NJNPI 1245203066
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $180,932 of the $214,529 with a category attached, or 84.3%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 60.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $120,715 and has fallen 100.0% since, to $19 in 2025. Among retina specialist clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $4378.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$130K
- Bausch & Lomb Americas Inc.$43K
- Alcon$15K
- Regeneron Healthcare Solutions, Inc.$10K
- Novartis$6K
- Dutch Ophthalmic, USA$4K
- plus $7K from 6 others
What the payments were for
- Consulting fees$30,46314%
- Speaking & faculty fees$180,93284%
- Travel & lodging$2,1571%
- Food & beverage$9770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $130,000 |
| Bausch & Lomb Americas Inc. | 2 | $42,500 |
| Alcon | 8 | $15,033 |
| Regeneron Healthcare Solutions, Inc. | 7 | $10,401 |
| Novartis | 6 | $5,747 |
| Dutch Ophthalmic, USA | 1 | $3,750 |
| Genentech USA, Inc. | 3 | $2,627 |
| Carl Zeiss Meditec, Inc. | 2 | $2,275 |
| Coherus Oncology, Inc. | 2 | $1,733 |
| Astellas Pharma US Inc | 6 | $320 |
| Alimera Sciences, Inc. | 4 | $101 |
| AbbVie(2 entities) | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$70,000
- STELLARIS PC$60,000
- Constellation$14,440
- EYLEA$10,312
- BEOVU$5,638
- EVA Ophthalmic Surgical System$3,750
- Lucentis$1,815
- VABYSMO$780
- Izervay$117
How this compares
$214,529 in reported general payments places this provider in the 90th percentile of 35 retina specialist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Restasis MultidoseCyclosporine | 14 | $8,890 |
| Bromfenac Sodium | 28 | $4,364 |
| ProlensaBromfenac Sodium | 11 | $3,920 |
| Difluprednate | 43 | $3,353 |
| Prednisolone Acetate | 54 | $2,230 |
| Latanoprost | 30 | $252 |
| Brimonidine Tartrate | 12 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis Multidose | $42 | $8,89014 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $130,000 | $3,92011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 retina specialist providers in New Jersey.
Other retina specialist in New Brunswick
- Howard FineNew Brunswick$955K
- Daniel RothNew Brunswick$61K
- Sumit ShahNew Brunswick$41K
- Harold WheatleyNew Brunswick$13K
- Bruce KeyserNew Brunswick$8K
- Eric FriedmanNew Brunswick$554
- Stuart GreenNew Brunswick$22
- Joshua MaliFlemington$230K
- Leonard FeinerUnion$72K
- Vatsal DoshiMillburn$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.